In this issue:
Anti-PD1 therapy for advanced OSCC
PD-1 inhibitor therapy for locally advanced OSCC
Bevacizumab + FOLFIRI in GEP NEC
The phase 2b NIFTY RCT
Adjuvant nab-paclitaxel + gemcitabine in resected PDAC
PD-1 antibody plus chemotherapy in OSCC
RT after chemotherapy in resected cholangiocarcinoma
Predictive markers for treatment response in PDAC
PD-L1 predicts prognosis for gastric cancer patients
CA19-9 response in patients with operable pancreatic cancer
Please login below to download this issue (PDF)